Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar

Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.

→ Srishti Gupta took over as CEO of Idorsia last summer, but the job is open again as chairman Jean-Paul Clozel kicks off another search.

Roche’s subsidiary Genentech has called off the late-stage development of a muscle-building drug in two rare genetic conditions, spinal muscular atrophy (SMA) and facioscapulohumeral muscular

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.